TEVA 3.150% 01Oct2026 Corp (USD)

Bond Factsheet

Matured/ Called

Teva Pharmaceutical Finance Netherlands III B.V.

Indicative

Full Lot

Bid Price

100.036

Change in Bid Price

remove 0.024

Bid Yield (%)

Change in Bid Yield

Ask Price

100.127

Change in Ask Price

remove 0.021

Ask Yield (%)

Change in Ask Yield

Indicative price as of 01 Oct 2026, 12:00am

chevron_leftchevron_right

Bond Information

Teva Pharmaceutical Finance Netherlands III B.V. operates as a special purpose entity. The Company was formed for the purpose of issuing debt securities to repay existing credit facilities, refinance indebtedness, and for acquisition purposes.

Bond Issuer

Teva Pharmaceutical Finance Netherlands III B.V.

Guarantor

Teva Pharmaceutical Industries Ltd

Announcement Date

18 Jul 2016

Issue Date

21 Jul 2016

Maturity Date

01 Oct 2026

Years to Maturity / Next Call

- / -

Modified Duration

Issue / Reoffer Price

99.734

Issue / Reoffer Yield

3.180

Coupon Type

Fixed

Annual Coupon Rate

3.150

Coupon Frequency

Semi Annually

Seniority

Senior Unsecured

Reference Rate

ISIN

US88167AAE10

CUSIP

88167AAE1

Bond Currency

USD

Total Issue Size

3,500,000,000

Outstanding Issue Size

1,798,479,000

Min. Investment Quantity (Nominal)

USD 2,000

Incremental Quantity (Nominal)

USD 1,000

Bond Type

Corporate

Bond Sector

Health Care

Bond Sub Sector

Pharmaceuticals

Issuer Credit Rating (S&P/ Fitch)

***/ N.R

Bond Credit Rating (S&P/ Fitch)

***/ BBB-

Shariah Compliant

Exchange Listed

Others

Bond Feature(s)

Make Whole Call

Teva Finance may redeem the notes of any series, in whole or in part, at anytime or from time to time, on at least 20 days’, but not more than 60 days’, prior notice. The notes of each series will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the notes to be redeemed and (2) the sum of the present values of the Remaining Scheduled Payments (as defined under “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) discounted, on a semi-annual basis(assuming a 360-day year consisting of twelve 30-day months), at a rate equal to the sum of the Treasury Rate (as defined in “Description of the Notes and the Guarantees—Optional Redemption by the Issuer”) plus 12.5 basis points, in the case of the 2018 notes, 15 basis points, in the case of the 2019 notes, 20basis points, in the case of the 2021 notes, 25 basis points, in the case of the2023 notes, 25 basis points, in the case of the 2026 notes, or 30 basis points, in the case of the 2046 notes, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

Additional Note

Special Mandatory Redemption

If the closing of the Actavis Generics (as defined below) acquisition does not occur on or prior to October 26, 2016, or if the transaction agreement, as amended, related to the Actavis Generics acquisition is terminated at any time prior thereto, the notes will be subject to a special mandatory redemption at a redemption price equal to 101% of their aggregate principal amount, plus accrued and unpaid interest, if any, from the date of initial issuance of the notes up to, but not including, the special redemption date. “Actavis Generics” means the worldwide generic pharmaceuticals business of Allergan plc and certain other assets.

Bondsupermart strives to ensure the accuracy and relevance of the information provided here. If the information is not up-to-date or erroneous, we appreciate feedback to keep it accurate.